Kennedy Keith sold $4.8M of CDNA
Kennedy Keith (CFO & COO) sold 61,961 shares of CareDx, Inc. (CDNA) at an average of $77.82 ($76.55–$83.60, $4.82M total) across 8 trades on 2026-11-05 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale reduces insider ownership and may be interpreted as a lack of confidence, potentially prompting short sellers.
Market read
The filing provides fresh, material information about insider activity that could affect CDNA's short‑term price.
What to watch
The CFO may be diversifying holdings; no change in company fundamentals is indicated.
Background
SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.
Ticker impact
CFO Kennedy Keith sold 61,961 shares for $4.8M via a 10b5‑1 plan, reducing his stake to 199,147 shares.
likely downward pressure as the market prices in the insider sell.
A $4.8M sale by a senior officer is material but not large enough to trigger a major move; traders may watch for further insider activity.
Market effects
Minimal impact on the broader biotech sector; the sale is company‑specific.
Limited to U.S. markets where CDNA trades.
Low global relevance.
Counterpoint
The sale could be a routine liquidity event under a pre‑arranged plan, not a negative signal.
Key entities
- companyCareDx, Inc.
Biotech firm listed on NASDAQ under CDNA.
- personKennedy Keith
CFO & COO of CareDx, reporting the insider sale.



